Abstract
Cytoprotection or metabolic modulation is a new principle in the treatment of angina pectoris. The effect of ranolazine (a cytoprotective drug) on ischemic threshold, coronary sinus blood flow, and myocardial metabolism was evaluated by means of two pacing sequences in nine male patients with coronary artery disease (CAD) and in eight male controls. Ranolazine was given as an intravenous bolus followed by continuous infusion; the mean total dose was 32.7 mg and 31.7 mg in patients and controls, respectively. Angina pectoris was relieved in two patients after ranolazine but pacing time to pain was unchanged in the remaining patients. Maximal ST depression was lower (p = 0.02), but pacing time to maximal and to 1-mm ST depression remained unchanged after the drug. Ranolazine had no overall influence on coronary sinus blood flow, cardiac oxygen consumption, blood pressure, and heart rate. Cardiac uptake of free fatty acids (FFA) was reduced (p = 0.01), and net uptakes of glucose (p = 0.07) and lactate (p = 0.06) tended to be lower after ranolazine in CAD patients and controls. Ranolazine had no direct influence on cardiac exchange of glutamate, alanine, and citrate or on the arterial concentration of any metabolite. In the present study ranolazine had minimal clinical effects. A decrease in myocardial FFA utilization, however, allows greater myocardial glucose oxidation, which may increase the energy production in relation to oxygen availability.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996;93:135–142.
Leiris J, Boucher F. Rationale for trimetazidine administration in myocardial ischaemia-reperfusion syndrome. Eur Heart J 1993;14(Suppl G):34–40.
Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 1992;20:131–138.
Detry JM. Clinical features of an anti-anginal drug in angina pectoris. Eur Heart J 1993;14(Suppl G):18–24.
Pouleur H, Hue L, Harlow BJ, Rousseau MF. Metabolic pathway modulation: A new approach to treat myocardial ischemia. Circulation 1989;80(Suppl II):52.
Thomassen AT, Nielsen TT, Bagger JP, Henningsen P. Myocardial exchanges of glutamate, alanine and citrate in controls and patients with coronary artery disease. Clin Sci 1983;64:33–40.
Bagger JP. Effects of antianginal drugs on myocardial energy metabolism in coronary artery disease. Pharmacol Toxicol 1990;66(Suppl IV):1–31.
Rasmussen K, Bagger JP, Bottzau J, Henningsen P. Prevalence of vasospastic ischaemia induced by the cold pressor test or hyperventilation in patients with severe angina pectoris. Eur Heart J 1984;5:354–361.
Bagger JP. Coronary sinus blood flow determination by the thermodilution technique: Influence of catheter position and respiration. Cardiovasc Res 1985;19:27–31.
Winer BJ, ed. Statistical Principles in Experimental Design. New York: McGraw-Hill, 1971.
Thadani U, Ezekowitz M, Fenney L, Chiang Y. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Circulation 1994;90:726–734.
Opie LH. Fuels: Carbohydrates and lipids. In: Opie LH, ed. The heart: Physiology and Metabolism. New York: Raven Press, 1991:208–246.
Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Ann Rev Physiol 1974;36:413–459.
Nielsen TT, Henningsen P, Bagger JP, Thomsen PEB, Eyjolfsson K. Myocardial citrate metabolism in control subjects and patients with coronary artery disease. Scand J Clin Lab Invest 1980;40:575–580.
Clarke B, Spedding M, Patmore L, McCormack JG. Protective effects of ranolazine in guinea pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br J Pharmacol 1993;109:748–750.
Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: Evidence for an indirect mechanism. J Moll Cell Cardiol 1996;28:341–350.
Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994;343:155–158.
Bagger JP, Nielsen TT, Thomassen AT. Reproducibility of coronary haemodynamics and cardiac metabolism during pacing-induced angina pectoris. Clin Physiol 1985;5:359–370.
Scott JC, Finkelstein LJ, Spitzer JJ. Myocardial removal of free fatty acids under normal and pathological conditions. Am J Physiol 1962;203:482–486.
Henning SL, Wambolt RB, Schönekess BO, Lopaschuk GD, Allard MF. Contribution of glycogen to aerobic myocardial glucose utilization. Circulation 1996;93:1549–1555.
Saddik M, Lopaschuk GD. Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem 1991;236:8162–8170.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bagger, J.P., Bøtker, H.E., Thomassen, A. et al. Effects of Ranolazine on Ischemic Threshold, Coronary Sinus Blood Flow, and Myocardial Metabolism in Coronary Artery Disease. Cardiovasc Drugs Ther 11, 479–484 (1997). https://doi.org/10.1023/A:1007705707667
Issue Date:
DOI: https://doi.org/10.1023/A:1007705707667